Neuromuscular Disorders
Volume 20, Issue 2 , Pages 102-110 , February 2010

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials

  • Linda J. Popplewell

      Affiliations

    • School of Biological Sciences, Royal Holloway – University of London, Egham, Surrey TW20 0EX, United Kingdom
    • These authors contributed equally to this paper.
    • ,
  • Carl Adkin

      Affiliations

    • Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom
    • These authors contributed equally to this paper.
    • ,
  • Virginia Arechavala-Gomeza

      Affiliations

    • Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom
    • ,
  • Annemieke Aartsma-Rus

      Affiliations

    • Center for Human and Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300RC Leiden, The Netherlands
    • ,
  • Christa L. de Winter

      Affiliations

    • Center for Human and Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300RC Leiden, The Netherlands
    • ,
  • Steve D. Wilton

      Affiliations

    • Centre for Neurological and Neuromuscular Disorders, Australian Neuromuscular Research Institute, University of Western Australia, Perth, WA 6009, Australia
    • ,
  • Jennifer E. Morgan

      Affiliations

    • Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom
    • ,
  • Francesco Muntoni

      Affiliations

    • Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom
    • ,
  • Ian R. Graham

      Affiliations

    • School of Biological Sciences, Royal Holloway – University of London, Egham, Surrey TW20 0EX, United Kingdom
    • ,
  • George Dickson

      Affiliations

    • School of Biological Sciences, Royal Holloway – University of London, Egham, Surrey TW20 0EX, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0)1784 443870; fax: +44 (0)1784 414224.

Received 13 July 2009 ,Revised 20 October 2009 ,Accepted 27 October 2009.

References 

  1. Hoffmann EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928
  2. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90–95
  3. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol. 2007;20:590–594
  4. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 2001;98:42–47
  5. Aartsma-Rus A, Janson AA, Kaman WE, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003;12:907–914
  6. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001;10:1547–1554
  7. Aartsma-Rus A, Janson AA, Kaman WE, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet. 2004;74:83–92
  8. Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JCT. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet. 2007;8:43–51
  9. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during pre-mRNA splicing in human muscle. Hum Gene Ther. 2007;18:798–810
  10. Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003;9:1009–1014
  11. Graham IR, Hill VJ, Manoharan M, Inamati GB, Dickson G. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med. 2004;6:1149–1158
  12. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, et al. Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther. 2004;10:232–240
  13. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther. 2008;16:1624–1629
  14. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local antisense dystrophin restoration with antisense oligonucleotide PRO051. N Eng J Med. 2007;357:2677–2687
  15. Kinali M, Arechavala-Gomeza V, Feng L, et al. Restoration of dystrophin expression in Duchenne muscular dystrophy: a single blind, placebo-controlled dose escalation study using morpholino oligomer AVI-4658. Lancet Neurol. 2009;8:918–928
  16. Arora V, Devi GR, Iversen PL. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol. 2004;5:431–439
  17. Heemskerk HA, de Winter CL, de Kimpe SJ, et al. In vivo comparison of 2′-O-methyl-PS and morpholino antisense oligonucleotides for DMD exon skipping. J Gene Med. 2009;11:257–266
  18. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet. 2003;12:1801–1811
  19. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006;12:175–177
  20. Malerba A, Thorogood FC, Dickson G, Graham IR. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther. 2009;20:955–965
  21. McClorey G, Fall AM, Moulton HM, et al. Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord. 2006;16:583–590
  22. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 2006;13:1373–1381
  23. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009;30:293–299
  24. Popplewell LJ, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther. 2009;17:554–561
  25. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther. 2007;15:1288–1296
  26. McCulley C, Adkin C, Fletcher S, Wilton SD, Morgan J, Wells DJ. Optimising the efficacy of morpholino antisense oligonucleotide induced exon-skipping in primary myoblasts using nucleofection, submitted for publication.
  27. ‘tHoen PAC, de Meijer EJ, Boer JM, et al. Generation and characterization of transgenic mice with the full-length human DMD gene. J Biol Chem. 2008;283:5899–5907
  28. Aartsma-Rus A, De Winter CL, Janson AAM, et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides. 2005;15:284–297
  29. Aartsma-Rus A, van Vliet L, Hirschi M, et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther. 2008;17:548–553
  30. Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther. 2007;15:157–166
  31. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 2004;11:1391–1398

PII: S0960-8966(09)00666-X

doi: 10.1016/j.nmd.2009.10.013

Neuromuscular Disorders
Volume 20, Issue 2 , Pages 102-110 , February 2010

Article Tools

* Image Usage & Resolution